Encision EBIT Margin
The EBIT Margin (Operating Margin) of Encision (ECIA) as of Jul 22, 2026 is -2.62 %. In the previous year, EBIT Margin (Operating Margin) was -9.73 % — a change of -73.03% (higher).
Get this data via API
Financial Data API
EBIT Margin
-2.62 %
YoY
-73.03%
Last updated:
EBIT Margin (Operating Margin) of Encision is 2026 -2.62 % . EBIT Margin (Operating Margin) of Encision was 2025 -9.73 % . It decreases by -73.03% higher compared to the previous year.
Encision's operating (EBIT) margin stands at -2.6%, down from -0.8% several years earlier.
Access this data via the Eulerpool API
Encision Stock analysis
What does Encision do? Encision Inc is a leading provider of precision instruments for minimally invasive surgery, based in Boulder, Colorado. The company's history can be traced back to 1991 when it was founded by Kenneth Messier, an experienced surgeon.
At that time, minimally invasive surgery was becoming increasingly popular as it offered patients smaller scars and less pain. However, the technology was not yet perfected and problems, particularly with the use of high-frequency electrocautery, kept arising.
Messier recognized this problem and developed an innovative solution: AEM technology (Active Electrode Monitoring). Together with a colleague, Mark Weinstein, he founded Encision Inc to bring this technology to the market.
Since then, the company has evolved into a leading provider of precision tools for minimally invasive surgery. Encision's business model is based on the production and distribution of medical devices and related consumables.
Encision offers a wide range of surgical instruments, including AEM and non-AEM electrocautery devices, surgical monitors, fine cutting instruments, and trocars. These devices are used in various surgical disciplines such as gynecology, urology, and general medicine.
One of Encision's main areas of focus is AEM technology, which reduces the risk of unintentional tissue burns during electrocautery. The AEM system continuously monitors the electrical impedance of the tissue and adjusts the high-frequency power as needed.
Another important area for Encision is the development of disposable products such as electrodes, needles, and tubing sets. These products are intended for single-use and help minimize infection risks.
Encision has also specialized in the development of instruments for laparoscopic surgery, a minimally invasive technique in which the operation is performed through small incisions in the body. Encision's laparoscopy instruments offer precise control and high performance to meet the demands of surgeons.
Encision has sold over 2,500 devices to clinics and healthcare providers in North America and Europe. Most of the products are registered and certified in the USA.
Encision places great emphasis on quality and innovation. The company has strict quality control measures to maintain the highest standards in production and the development of new products. Furthermore, it is committed to constantly developing new technologies and expanding its portfolio to meet customer needs.
Overall, Encision Inc has experienced strong growth in recent years and has become a leading provider of surgical instruments in the minimally invasive surgery industry. With its focus on quality, innovation, and customer satisfaction, the company has built a solid reputation in the industry and is expected to continue being a key player in the future.
The answer is "Encision Inc is a leading provider of precision instruments for minimally invasive surgery, based in Boulder, Colorado." Encision is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Encision stock
EBIT Margin (Operating Margin) of Encision is -2.62 % in 2026.
Access this data via the Eulerpool API
Margins — Encision
All Key Metrics — Encision
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth